PT-141
The Sexual Health Peptide That Works Differently
PT-141 (bremelanotide) is the only treatment that addresses low sexual desire through the central nervous system rather than the vascular system. Available for both men and women. Works where Viagra, Cialis, and HRT cannot reach.
Every Other Sexual Health Treatment Works Peripherally. PT-141 Works Centrally.
PDE-5 inhibitors like sildenafil and tadalafil improve blood flow to genital tissue. HRT restores the hormonal environment. These are peripheral interventions — they address the physical plumbing and biological conditions required for sexual function. But they cannot create desire. Desire originates in the brain, through neurological pathways that respond to completely different signals. PT-141 is the only treatment that activates those pathways directly. If the problem is “I don’t feel desire” rather than “I can’t perform,” PT-141 is addressing the actual mechanism.
A Different Pathway Than Anything Else Available
PT-141 is a melanocortin receptor agonist. It binds to melanocortin receptors (MC3R and MC4R) in the hypothalamus and other brain regions that regulate sexual behavior and arousal. This activates the neurological pathways associated with spontaneous sexual desire — not arousal in response to stimulation, but the motivated, anticipatory desire that precedes it. This is what HSDD patients are missing: the desire that doesn’t require a specific trigger to appear.
This mechanism is entirely separate from vascular and hormonal pathways. PT-141 does not increase blood flow to genital tissue (PDE-5 inhibitors do that). It does not restore estrogen or testosterone levels (HRT does that). It activates the neurological arousal network in the brain. The three pathways are complementary — PT-141 can be used alongside HRT or PDE-5 inhibitors when multiple mechanisms are contributing to the problem.
PT-141 is FDA-approved under the brand name Vyleesi® for HSDD in premenopausal women — the only FDA-approved treatment for this specific indication. It is also prescribed off-label for postmenopausal women and for men with low libido. Our providers evaluate your clinical picture, hormone levels, medications, and health history before prescribing.
Book Free ConsultationSildenafil and tadalafil improve erectile function by increasing blood flow. PT-141 increases desire and arousal through the brain’s melanocortin system. Entirely different pathways — and they can be used together when both mechanisms are contributing to the problem.
Different Problems. Different Mechanisms. All Three May Apply.
PT-141 fills a gap that no other sexual health treatment addresses.
Sildenafil (Viagra), tadalafil (Cialis), vardenafil. Block phosphodiesterase-5, increasing cGMP and relaxing smooth muscle in genital vasculature. Increases blood flow to erectile tissue.
Estradiol, testosterone, progesterone. Restores the hormonal environment required for tissue health, lubrication, and baseline desire. Addresses deficiency as the underlying cause.
PT-141 (bremelanotide). Binds MC3R and MC4R receptors in the hypothalamus. Activates the brain’s motivational arousal network — producing spontaneous sexual desire independent of hormonal levels or blood flow.
PT-141 for Women and Men
PT-141 is FDA-approved specifically for HSDD in premenopausal women — the only FDA-approved treatment for this indication. The most responsive patients are women whose low desire has a central (neurological) component rather than a purely hormonal one. That said, PT-141 and HRT address different mechanisms and work well in combination: HRT restores the hormonal foundation, PT-141 activates the neurological desire network that sits on top of it.
PT-141 is also used off-label for postmenopausal women with HSDD, including those already on adequate HRT who still experience absent or severely diminished desire. Our providers evaluate the full hormonal picture alongside PT-141 candidacy at every consultation.
Women’s sexual wellness guideIn men, PT-141 is prescribed off-label for low libido and reduced sexual desire — specifically for cases where PDE-5 inhibitors address the mechanical erectile component but desire itself remains absent or significantly diminished. This pattern is particularly common in men with low testosterone, men on SSRIs, and older men whose erectile function responds to medication but whose interest in sex has declined independently.
PT-141 can be combined with sildenafil, tadalafil, or TRT when multiple mechanisms are contributing. Dr. Ashar coordinates the full protocol including interactions and cardiovascular contraindications.
Men’s sexual health guide
Most Patients Have Already Tried Everything Else.
The patients who seek out PT-141 are typically not new to the problem. They’ve been on HRT. They’ve been told their hormones are “fine.” Their partners don’t understand what’s wrong. They don’t understand what’s wrong. The desire is simply absent, and no explanation has fit until someone explains that desire is a brain function, not a hormone level.
PT-141 is not a replacement for HRT. It is not a replacement for testosterone. It fills the neurological gap that those treatments cannot reach — the motivational network that generates desire before any physical arousal begins. For patients with central HSDD, it is often the missing piece.
PT-141 Dosing and Protocol
Nausea management: Taking 1.75mg instead of 2mg reduces nausea significantly. Many patients take an OTC anti-nausea medication (ondansetron or dimenhydrinate) 30 minutes before injecting. Staying hydrated and avoiding high-fat meals before dosing also reduces nausea frequency. Our providers discuss personalized nausea management at your consultation.
Dr. Ashar N.
Dr. Ashar holds a Doctor of Nursing Practice and two national board certifications, one in family practice and one in psychiatric mental health.
She founded Tactus Health to close the gap she watched her own family fall through: symptoms that were real, labs that came back normal, and no one willing to connect the two.
She is responsible for the protocols our medical team follows, and for the training of the clinicians who deliver them. Holding both certifications is why those protocols treat hormones, mood, sleep and metabolism as one system rather than five separate appointments.
Consult with Our Medical Team by Telehealth
PT-141 is available via telehealth to patients by telehealth. No in-person visit required. Medication ships in plain packaging directly to your door within days of your prescription.
PT-141 FAQ
Yes. PT-141 is the research name for bremelanotide, the active molecule in Vyleesi®. Vyleesi is the FDA-approved brand-name version for HSDD in premenopausal women. Compounded bremelanotide (PT-141) contains the same active molecule and is prescribed when compounded formulations are clinically appropriate or when brand-name access is a barrier to treatment.
PT-141 is a subcutaneous (under the skin) injection administered approximately 45 minutes before anticipated sexual activity. Standard dose is 1.75mg. It is not taken daily — it is as-needed only. Maximum one dose per 24 hours. Most patients find the injection straightforward with the pre-filled pen format. Dr. Ashar provides complete self-injection instructions with every prescription.
Nausea is the most common side effect, occurring in approximately 40% of patients in clinical trials. It typically peaks 1 to 3 hours after injection and resolves within 24 hours. Flushing, injection site reactions, and headache also occur. Transient blood pressure increases have been reported. PT-141 is contraindicated in patients with cardiovascular disease or uncontrolled hypertension. A full medical history review is required before prescribing.
Yes, and this combination is frequently the most effective approach. PT-141 activates the neurological desire pathway. HRT provides the hormonal foundation. PDE-5 inhibitors support the vascular component. The three mechanisms are independent and complementary. Dr. Ashar coordinates the full protocol including any interactions, dosing timing, and cardiovascular considerations when combining treatments.
Yes, available via telehealth to patients by telehealth. Our providers conduct the consultation via video visit, review your health history and any contraindications, and send your prescription to a compounding pharmacy for discreet direct shipment. No in-person visit required.
Both are FDA-approved for HSDD but through completely different mechanisms. Flibanserin (Addyi) is taken daily and works through serotonin and dopamine receptor modulation over weeks. It requires strict alcohol avoidance and has significant drug interactions. PT-141 is as-needed, works within 45 minutes through the melanocortin system, and does not have the alcohol restriction. Most patients and clinicians find PT-141 more practical for on-demand use. Our providers discuss which approach fits your situation at consultation.
Start Your PT-141 Consultation.
Free consultation with Dr. Ashar. Discreet billing. Ships in plain packaging within days of prescription.
Available for men and women · Telehealth available
Important Safety Information: PT-141 (bremelanotide) is a prescription peptide requiring clinical evaluation before prescribing. FDA-approved as Vyleesi® for HSDD in premenopausal women; off-label for men and postmenopausal women. Contraindicated in patients with cardiovascular disease, uncontrolled hypertension, or known hypersensitivity to bremelanotide. Most common adverse effects: nausea (40%), flushing, headache, injection site reactions. Transient blood pressure increases reported. Not for daily use. Maximum 2 to 3 doses per week. Compounded bremelanotide is not FDA-approved as a finished drug product. All prescriptions issued by Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC. Telehealth available by telehealth. Individual results vary. Questions: [email protected] | (678) 892-9230 | 1400 Buford Hwy NE Suite K 2, Sugar Hill, GA 30518.